Gilead Stock News

In 1992, about 412 companies had an initial public offering (IPO) in the United States.

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally a

Korn Ferry, Gilead Sciences, Qualcomm, Ralph Lauren, and Manpower are identified as five companies with high dividend yields and strong capacity for future dividend increases. Korn Ferry is a leader i

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Gilead Sciences Inc. (GILD, Financial) is an American pharmaceutical company specializing in developing and commercializing medicines to treat patients with HIV, large B-cell lymphoma, chronic hepatit

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 p

Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Partic

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

Johnson & Johnson NYSE: JNJ,  Gilead Sciences Inc. NYSE: GILD and Bristol Myers Squibb Co. NYSE: BMY are among healthcare sector dividend-payers trading at low valuations relative to their earnings.

Gilead Sciences, Inc. (NASDAQ:GILD ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Particip

AbbVie is a Dividend King with a bright future. Eli Lilly's dividend is just icing on the cake, with the company's growth prospects taking center stage.

We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD,

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.